Objectives: Hyperglycemia that develops during pregnancy is a diagnostic criterion of gestational diabetes mellitus (GDM). Current studies have shown that the expression of miRNA-181d is significantly enhanced in the glomeruli of type 2 diabetic. However, the relationship between miR-181d and GDM has never been reported before.
Material and methods: The serum samples were collected from patients with GDM and subjected to qRT-PCR to verify the potential altered the miR-181d expression. In an in vitro GDM model, the miR-181d expression was induced by high glucose treatment, a miR-181d inhibitor was transfected into INS-1 cells to reduce miR-181d expression. Then, the level of insulin mRNA, cell viability, and content of total insulin were analyzed through ELISA, CCK-8 assay, and qRT-PCR assay. The relative apoptosis rates were detected by Annexin-V/PI assays. Finally, the shIRS2 transfection was performed to test whether in pancreatic β cells, IRS2 had similar insulin-enhancing functions as the miR-181d inhibitor.
Results: MiR-181d expression level was positively correlated with fasting blood glucose levels and the inhibition of miR-181d reduced insulin resistance, enhanced cells viability and suppressed high-glucose-induced apoptosis. In addition, the suppression of miR-181d improved the functions of INS-1 cells by targeting IRS2.
Conclusions: In summary, this study indicated that miR-181d modulated the process of insulin signaling and cell viability and apoptosis in pancreatic β cells by targeting IRS-2, suggesting that miR-181d inhibition is a potential target for GDM therapy.
Keywords: IRS2; gestational diabetes mellitus; insulin resistance; miR-181d; pancreatic beta cell.